WaveMan
WaveMan · Company
FENC · Fennec Pharmaceuticals Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

FENC Fennec Pharmaceuticals (FENC) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001211583
Quote by TradingView
Form 144 · 5
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
71
13F, latest reported quarter
Conversions, 180 days
6
Codes C/M, not in net · $294.3K priced

What the filings say about FENC

Insiders, 180 days
-$1.7M net sold
5 sellers · 33% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.4M
5 notices

Fennec Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, FENNEC PHARMACEUTICALS INC. insiders sold a net $1.7M of stock across 94 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Brughera Marco Maria
Director
SELL
2026-09-16 SECtraded 2026-09-15
15,545
$160.0K
-5.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • 3 other insiders sold within 30 days.
  • 71 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Brughera Marco Maria sold about $160.0K of FENC under a 10b5-1 plan on Sep 15, 2026; 3 other insiders sold within 30 days and 71 funds added in the latest 13F quarter.
Raykov Rosty
SELL
2026-09-01 SEC
10,000
$121.1K
-17.5%
Context
  • 43 earlier Form 4 trades (code P or S) here by this insider (43 sales), the last on Aug 3, 2026.
  • The trade is 8.0% of the 124,411 shares held after it.
  • 3 other insiders sold within 30 days.
  • 71 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Raykov Rosty sold about $121.1K of FENC under a 10b5-1 plan on Sep 1, 2026; 3 other insiders sold within 30 days and 71 funds added in the latest 13F quarter.
Sayad Pierre Sargis
Chief Medical Officer
SELL
2026-08-31 SEC
12,000
$146.2K
-15.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 126.1% of the 9,519 shares held after it.
  • 3 other insiders sold within 30 days.
  • 71 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Sayad Pierre Sargis sold about $146.2K of FENC on Aug 31, 2026; 3 other insiders sold within 30 days and 71 funds added in the latest 13F quarter.
Andrade Robert
CHIEF FINANCIAL OFFICER
SELL
2026-08-28 SECtraded 2026-08-27
75,000
$883.5K
-17.8%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Mar 26, 2024.
  • The trade is 34.5% of the 217,675 shares held after it.
  • 3 other insiders sold within 30 days.
  • 71 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER Andrade Robert sold about $883.5K of FENC under a 10b5-1 plan on Aug 27, 2026; 3 other insiders sold within 30 days and 71 funds added in the latest 13F quarter.
Raykov Rosty
SELL
2026-08-04 SECtraded 2026-08-03
10,000
$95.8K
-3.5%
Context
  • 42 earlier Form 4 trades (code P or S) here by this insider (42 sales), the last on Jul 1, 2026.
  • The trade is 7.6% of the 131,633 shares held after it.
  • 2 other insiders sold within 30 days.
  • 71 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Raykov Rosty sold about $95.8K of FENC on Aug 3, 2026; 2 other insiders sold within 30 days and 71 funds added in the latest 13F quarter.
94 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 89 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.7M over 180 days
-$1.4M over 90 days
below 69% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
71 funds bought in last quarter
more than 56% of Pharma & Biotech
Revenue
-6.1% year over year
below 63% of Pharma & Biotech
Margin
-21.8% net margin
more than 57% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
2.6% of the float short (float per yahoo 2026-10-26) · 3.9 days to cover · settled 2026-09-30
below 69% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch FENC

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+13.3%12M
-36%-10%+17%+43%2025-102025-122026-022026-042026-062026-082026-10 2025-12-24 · Southpoint Capital Advisors LP sold $7.5M2025-11-14 · Southpoint GP, LLC sold $1.3M2026-08-27 · Andrade Robert sold $883.5K2025-11-17 · Southpoint GP, LLC sold $755.2K2025-11-18 · Southpoint Capital Advisors LLC sold $170.0K2026-09-15 · Brughera Marco Maria sold $160.0K2026-08-31 · Sayad Pierre Sargis sold $146.2K2026-09-01 · Raykov Rosty sold $121.1K2026-07-01 · Raykov Rosty sold $99.9K2026-08-03 · Raykov Rosty sold $95.8K2026-06-01 · Raykov Rosty sold $93.8K2026-03-02 · Raykov Rosty sold $84.3K2025-11-05 · Raykov Rosty sold $81.0K2026-02-02 · Raykov Rosty sold $80.3K2026-01-02 · Raykov Rosty sold $78.4K2025-12-05 · Raykov Rosty sold $75.4K2026-05-01 · Raykov Rosty sold $69.8K2026-04-01 · Raykov Rosty sold $69.1K2026-05-11 · RALLIS CHRIS A sold $58.8K2026-09-15 · MARCO BRUGHERA filed to sell $160.1K2026-09-01 · ROSTISLAV RAYKOV filed to sell $121.2K2026-08-31 · PIERRE S SAYAD filed to sell $146.2K2026-08-27 · ROBERT ANDRADE filed to sell $883.9K2026-08-03 · ROSTISLAV RAYKOV filed to sell $95.8K2026-07-01 · ROSTISLAV RAYKOV filed to sell $100.0K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns FENC: institutional holders (13F)

13F holdings, latest reported quarter
Rosalind Advisors, Inc.
3,188,001 sh
$34.3M
AIGH Capital Management LLC
2,486,038 sh
$26.7M
Solas Capital Management, LLC
1,889,366 sh
$20.3M
BlackRock, Inc.
1,727,069 sh
$18.6M
AWM Investment Company, Inc.
1,160,296 sh
$12.5M

Congress trades in FENC

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

FENC planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
MARCO BRUGHERA
Filed 2026-09-15
$160.1K
ROSTISLAV RAYKOV
Filed 2026-09-01
$121.2K
PIERRE S SAYAD
Filed 2026-08-31
$146.2K
ROBERT ANDRADE
Filed 2026-08-27
$883.9K
ROSTISLAV RAYKOV
Filed 2026-08-03
$95.8K

FENC mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$1.2M position · as of 2026-06-30
1.2%
iShares Micro-Cap ETF
$1.0M position · as of 2026-06-30
0.1%
Invesco Russell 2000 Dynamic Multifactor ETF
$181.0K position · as of 2026-05-31
0.1%
GuideMark Small/Mid Cap Core Fund
$49.3K position · as of 2026-06-30
0.0%
Franklin U.S. Small Cap Multifactor Index ETF
$18.3K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$70.2K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.7M sold by insiders over 180 days, 71 funds added last quarter, $1.4M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

FENC financials

Revenue growth
-6.1%
XBRL, annual
Net margin
-21.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$59.2M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-16,438%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.46x
LongTermDebt as filed 2025-09-30 (9 months older than the period end) (includes the current portion); equity 2026-06-30
Cash flow to debt
-0.11x
TTM operating cash flow over LongTermDebt as filed 2025-09-30 (9 months older than the period end) (includes the current portion)
Return on equity
-55,659%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-16,140%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-2.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$334.1M
market value at close 2026-10-26 on 2026-08-11 shares, plus LongTermDebt as filed 2025-09-30 (9 months older than the period end) (includes the current portion), minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$44.6M$47.5M$23.8M$1.8M
Gross profitn/an/a$20.0M$1.4M
Operating income-$6.3M$2.6M-$12.8M-$22.6M
Net income-$9.7B-$436.0M-$16.0B-$23.7M
EPS (diluted)-0.34-0.02-0.60-0.90
Operating cash flow-$12.5M$27.0M-$17.1M-$18.1M
Cash$36.8M$26.6M$13.3M$23.8M
Long-term debtn/a$19.3M$30.9M$24.9M
SEC XBRL, fiscal years, as known on 2026-10-28

FENC Stock Sonar score 6/7 axes

Find similar shapesCompare

FENC ranks highest on risk and compliance (79th percentile) and institutional and government (56th), and lowest on insider conviction (20th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
28
Inputs
  • Return on equity-55659% · 0 pct, sector of 545
  • Return on assets-16140% · 1 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-2.3% · 84 pct, sector of 576
Financial health
51
Inputs
  • Debt to equity0.46x · 34 pct, sector of 352
  • Cash flow to debt-0.11x · 67 pct, sector of 371
Growth
37
Inputs
  • Revenue growth, YoY-6.1% · 37 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
20
Inputs
  • Net Form 4 buying (codes P and S), 180d-$564K · 40 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
56
Inputs
  • Funds adding, latest quarter71 · 56 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
79
Inputs
  • Short interest, % of float+2.6% · 69 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+3.7% · 89 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

FENC filings, in plain words

Are Fennec Pharmaceuticals insiders buying or selling FENC?

In the 180 days to 2026-10-28, Fennec Pharmaceuticals insiders were net sellers, a net $1.7M across purchases and sales reported on Form 4, by 5 sellers.

Are there planned insider sales of FENC?

Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.4M of stock; the latest, by MARCO BRUGHERA, was filed 2026-09-15.

Read the full summary

In the 180 days to 2026-10-28, Fennec Pharmaceuticals insiders were net sellers of FENC, a net $1.7M across purchases and sales reported on Form 4 by 5 sellers. 33% of the 9 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.4M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies